Inventiva Revises Phase III NASH Plans For Broader Indication

 
• By Joseph Haas

While plans to obtain accelerated approval of lanifibranor remain unchanged, Inventiva now plans to conduct the confirmatory Phase III in cirrhotic patients, meaning a shorter trial duration and possibly broader label.

Change of plans
Inventiva's revised Phase III NASH plans involve testing drug in cirrhotic patients • Source: Shutterstock

More from Clinical Trials

More from R&D